<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03945279</url>
  </required_header>
  <id_info>
    <org_study_id>261AS101</org_study_id>
    <nct_id>NCT03945279</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>A Phase 1, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adult Participants With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety, tolerability of
      single-ascending doses of BIIB100 in adults with amyotrophic lateral sclerosis (ALS). The
      secondary objective of the study is to characterize the pharmacokinetic profile of BIIB100.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Screening (Day -28 ) up to Day 15</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, or is a medically important event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of BIIB100</measure>
    <time_frame>Day 1 (pre-dose) up to Day 3</time_frame>
    <description>BIIB100 will be measured in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of BIIB100</measure>
    <time_frame>Day 1 (pre-dose) up to Day 3</time_frame>
    <description>BIIB100 will be measured in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of BIIB100</measure>
    <time_frame>Day 1 (pre-dose) up to Day 3</time_frame>
    <description>BIIB100 will be measured in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax (Tmax) of BIIB100</measure>
    <time_frame>Day 1 (pre-dose) up to Day 3</time_frame>
    <description>BIIB100 will be measured in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) of BIIB100</measure>
    <time_frame>Day 1 (pre-dose) up to Day 3</time_frame>
    <description>BIIB100 will be measured in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of BIIB100</measure>
    <time_frame>Day 1 (pre-dose) up to Day 3</time_frame>
    <description>BIIB100 will be measured in the plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During the Terminal Elimination (Vz/F) of BIIB100</measure>
    <time_frame>Day 1 (pre-dose) up to Day 3</time_frame>
    <description>BIIB100 will be measured in the plasma.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1: BIIB100 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose of BIIB100 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: BIIB100 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose of BIIB100 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: BIIB100 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose of BIIB100 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: BIIB100 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose of BIIB100 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: BIIB100 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single oral dose of BIIB100 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1-5: Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive single oral dose of matching placebo on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB100</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Cohort 1: BIIB100 Dose 1</arm_group_label>
    <arm_group_label>Cohort 2: BIIB100 Dose 2</arm_group_label>
    <arm_group_label>Cohort 3: BIIB100 Dose 3</arm_group_label>
    <arm_group_label>Cohort 4: BIIB100 Dose 4</arm_group_label>
    <arm_group_label>Cohort 5: BIIB100 Dose 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>Cohort 1-5: Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must meet the laboratory-supported probable, probable, or definite criteria for
             diagnosing ALS according to the World Federation of Neurology El Escorial criteria.

          -  Participants taking concomitant riluzole at study entry must be on a stable dose for
             greater than or equals to (&gt;=) 30 days prior to the first dose of study treatment (Day
             1). Participants taking concomitant riluzole must be willing to continue with the same
             dose regimen throughout the study, unless the Investigator determines that riluzole
             should be discontinued for medical reasons, in which case it may not be restarted
             during the study.

          -  Participants taking concomitant edaravone at study entry must be on a stable dose for
             &gt;= 60 days prior to the first dose of study treatment (Day 1).

          -  Adequate respiratory function as indicated by slow vital capacity (SVC) &gt;= 65% of
             predicted value as adjusted for sex, age, and height (from the sitting position).

        Key Exclusion Criteria:

          -  Ongoing medical condition (e.g., wasting or cachexia, severe anemia) that would, in
             the opinion of the Investigator, interfere with the conduct or assessments of the
             study.

          -  Significant cognitive impairment or unstable psychiatric illness, including psychosis,
             suicidal ideation, suicide attempt, or untreated major depression less than or equals
             to (&lt;=) 90 days of Screening, which in the opinion of the Investigator would interfere
             with the study procedures.

          -  Treatment with drugs that are transported by Breast Cancer Resistance Protein (BCRP)
             and P-glycoprotein (P-gp) including, but not limited to, rosuvastatin, sulfasalazine,
             dabigatran, digoxin and fexofenadine.

          -  Current enrollment or plan to enroll in any interventional clinical study in which an
             investigational treatment or approved therapy for investigational use is administered
             within 30 days or 5 half-lives of the agent, whichever is longer, prior to the
             Baseline Visit (pre-dose on Day 1). Participation in a noninterventional study focused
             on ALS natural history may be allowed at the discretion of the Investigator and after
             consultation with the Sponsor.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>Fulton.Research@DignityHealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosemarie Previte</last_name>
      <phone>858-246-1319</phone>
      <email>rprevite@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>904-953-6912</phone>
      <email>mayofloridaALSresearch@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University, Dept of Neurology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>410-502-0495</phone>
      <email>emosmil1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>21219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506-2960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispecialty Research NOCCR/VRG</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alliance for Multispeciality Research NOCCR/VRG</last_name>
      <phone>865-305-9100</phone>
      <phone_ext>302 or 303</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>http://www.biogenclinicaldatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

